[Ip-health] Drugs watchdog condemns Roche for high price of breast cancer therapy

Elizabeth Rajasingh elizabeth.rajasingh at keionline.org
Fri Aug 8 09:57:19 PDT 2014


An interesting look at the cost of Roche's Kadcyla, in light of the NICE's
decision to decline NHS use.

http://www.theguardian.com/society/2014/aug/08/drugs-watchdog-nice-roche-breast-cancer-nhs-limit

"The pharmaceuticals giant Roche has been criticised in unprecedented terms
by the government's drugs watchdog for refusing to significantly lower the
price of a breast cancer
<http://www.theguardian.com/society/breast-cancer> drug
whose £90,000-per-patient cost is well over the NHS
<http://www.theguardian.com/society/nhs>'s limit.... Nice decides on
whether medicines are cost-effective for the NHS to buy. The watchdog
cannot approve drugs for use in the NHS that cost more than £30,000 per
patient, but is prepared to raise that ceiling to £50,000 for end-of-life
treatments such as Kadcyla."

another interesting take on the issue:

http://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/11021272/Why-is-Roches-new-breast-cancer-drug-so-expensive.html

----
Elizabeth Rajasingh
Perls Fellow, Knowledge Ecology International
1621 Connecticut Ave. NW, Suite 500
Washington, DC 20009
*elizabeth.rajasingh at keionline.org <elizabeth.rajasingh at keionline.org>* |
 1-202-332-2670



More information about the Ip-health mailing list